Advances in cryptorchidism, VUR deliver key benefits

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.